MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

Medications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A University of Dundee spin-out has formed a new company dedicated to developing new obesity therapies that avoid the muscle ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

A nutrition expert has shared a list of six types of foods that could help you to feel full for longer - and they may even ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.